Catch up on HCPLive’s top EADV 2026 psoriasis coverage, from head-to-head TYK2 inhibitor data to 2-year oral IL-23 results in high-impact disease sites.

Catch up on HCPLive’s first-half Fall Clinical 2026 coverage, including new psoriasis and atopic dermatitis data and expert insights on HS and vitiligo.

Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.

New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.

Weltruza requires no loading doses, oral supplementation, or post-injection monitoring, with approval based on the phase 3 SOLARIS trial.

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

A roundup of highlights from EADV Congress 2026 in Vienna, spanning dupilumab real-world data, pipeline biologics, and a first-in-class oral agent.

Among 155 patients aged 0 to 24 months, 96.1% of episodes were food-triggered and 90.4% of epinephrine recipients received only 1 dose.